Opportunistic Infections/Immunocompromised hosts Flashcards
Neutropenia associated with
Bacterial infections (especially gram negatives/pseudomonas)
Prolonged neutropenia associated with
Fungi
T cell associated with
Viruses, Fungi, PJP, Mycobacteria
Complement (or eculuzimab) with
Meningococcus
Infliximab associated with
TB
Asplenia associated with
Encapsulated organisms (HiB, Pneumococcal)
CBG associated with
Catalase positive organisms (Staph Aureus, Serratia, Nocardia, Burkholderia, Aspergillus)
Cat bite
Pasteurella multocida
Cat scratch
Bartonella henselae
Cat faeces/litter
Toxoplasmosis
Sickle cell disease
Salmonella species
Well toddler with BJI/normal CRP
Kingella kingae
Varicella PEP in immunocompetent host
Vaccine within 3 days could prevent, vaccine within 5 days reduces severity
Varicella PEP in immunocompromised host
VZIg- can give up to 10 days after exposure, but give ASAP
COVID treatment in immunocompromised
Dexamethasone, IV Remdesivir, PO Paxlovid
Rotavirus treatment in immunocompromised
Immunoglobulin
Adenovirus in immunocompromised host features
Conjunctivitis, colitis, pneumonitis, hepatitis, haemorrhagic cystitis
Adenovirus treatment in immunocompromised host
Cidofovir
RSV treatment in immunocompromised host
Nebulised/IV Ribavirin
Influenza and Paraflu treatment in immunocompromised host
Oseltamivir
BK and JC virus presentation in immunocompromised host
Haematuria/haemorrhagic cystitis
BK and JC virus treatment in immunocompromised
Cidofovir
Herpes virus that is not oncogenic
HHV-6 (causes febrile seizures)
Virus implicated in PTLD
EBV (lymphoblast proliferation)
PTLD spectrum
Glandular fever –> monoclonal proliferation –> Lymphoma
PTLD solid organ implicated
Solid organ (lung/liver/heart > renal)–> amount of lymphoid tissue
PTLD immune risks
First two years post transplant, EBV positive organ for EBV negative recipient, heavy immune suppression
PTLD treatment
Reduce immune suppression, Rituximab, Chemo